Gaurav Raturi1, Paramjit Kaur2, Gagandeep Kaur3. 1. Department of Transfusion Medicine, Shri Guru Ram Rai Institute of Health and Medical Sciences, Dehradun, India. 2. Department of Transfusion Medicine, Government Medical College and Hospital, Chandigarh, India. Electronic address: paramjit.gp71@yahoo.com. 3. Department of Transfusion Medicine, Government Medical College and Hospital, Chandigarh, India.
Abstract
OBJECTIVES: The present study was aimed to find out the prevalence of parvovirus B19 amongst healthy blood donors and blood transfusion recipients so as to determine the feasibility of providing seronegative blood components to vulnerable recipients. METHODS: A total of 1000 samples were studied which included 800 blood donors and 200 transfusion recipients.The transfusion recipients included 100 multitransfused patients and 100 non transfused controls.All samples were subjected to parvovirus B19 ELISA for IgG and IgM antibodies. RESULTS: Of the 800 blood donors,663(82.9%) were voluntary while 137(17.1%) were replacement donors.The seroprevalence of B19V IgG antibodies among healthy blood donors was found to be 34.1% whilst that of IgM antibodies was 1.4%.The seroprevalence of B19 V IgG antibodies was found to be 28.4% in the age group 18-35 years and 42.1% in donors more than 35 years of age(p ≤ 0.01). The overall seroprevalence of IgG antibodies in multitransfused patients was 34% and IgM antibodies was 7.0%.The B19 V IgG prevalence was 20% in the transfused patients aged 0-20 years and 48% in patients above 20 years of age (p ≤ 0.05). CONCLUSION: The moderately high seroprevalence of B19 V IgG in blood donors and patients suggests endemicity of infection.However, prevalence of B19 V IgM antibodies in blood donors is low.With the widespread use of pooled plasma derived medicinal products and recognition of severe pathological effects in susceptible recipients, transfusion transmission of B19 V has become a major concern in the past few decades.We suggest screening of blood units to identify B19 V IgM negative units for transfusion to selected patients.
OBJECTIVES: The present study was aimed to find out the prevalence of parvovirus B19 amongst healthy blood donors and blood transfusion recipients so as to determine the feasibility of providing seronegative blood components to vulnerable recipients. METHODS: A total of 1000 samples were studied which included 800 blood donors and 200 transfusion recipients.The transfusion recipients included 100 multitransfused patients and 100 non transfused controls.All samples were subjected to parvovirus B19 ELISA for IgG and IgM antibodies. RESULTS: Of the 800 blood donors,663(82.9%) were voluntary while 137(17.1%) were replacement donors.The seroprevalence of B19V IgG antibodies among healthy blood donors was found to be 34.1% whilst that of IgM antibodies was 1.4%.The seroprevalence of B19 V IgG antibodies was found to be 28.4% in the age group 18-35 years and 42.1% in donors more than 35 years of age(p ≤ 0.01). The overall seroprevalence of IgG antibodies in multitransfused patients was 34% and IgM antibodies was 7.0%.The B19 V IgG prevalence was 20% in the transfused patients aged 0-20 years and 48% in patients above 20 years of age (p ≤ 0.05). CONCLUSION: The moderately high seroprevalence of B19 V IgG in blood donors and patients suggests endemicity of infection.However, prevalence of B19 V IgM antibodies in blood donors is low.With the widespread use of pooled plasma derived medicinal products and recognition of severe pathological effects in susceptible recipients, transfusion transmission of B19 V has become a major concern in the past few decades.We suggest screening of blood units to identify B19 V IgM negative units for transfusion to selected patients.